Perspectives on Retinal Fluid Management in nAMD and DME

EP: 1.Navigating Step Therapy in nAMD and DME

EP: 2.Role of Biosimilars in nAMD and DME Step Therapy

EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg

EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice

Now Viewing

EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME

EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies

EP: 7.Using Steroids in DME Treatment

EP: 8.Patient Selection for New nAMD and DME Therapies

EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg

EP: 10.Safety Considerations for New Therapies

EP: 11.Promoting Treatment Adherence in nAMD and DME

Summary

Experts discuss the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) with a focus on fluid management using OCT imaging. They emphasize the importance of distinguishing between different types of fluid accumulation, such as intra-retinal, sub-retinal, and sub-RPE fluid, and its impact on visual acuity outcomes. They highlight findings from studies indicating that intra-retinal fluid is particularly detrimental to visual outcomes in both diseases. Additionally, they discuss the importance of minimizing fluid fluctuations over time to prevent worse visual outcomes and increased fibrosis. The physicians also mention the variability in response to treatment among patients and the need to consider switching treatment agents if necessary, particularly in cases where patients remain wet despite ongoing treatment.

This summary was AI-generated and edited for clarity.